ライフサイエンスコーパス: exisulind

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 re fed diets containing 0%, 0.06%, and 0.12% exisulind.

2 d PDE-2 expression, which are the targets of exisulind.

3 Exisulind (125 mg orally bid) in combination with capeci

4 we studied the effects of sulindac sulfone (exisulind), a non- cyclooxygenase-inhibitory end metabol

5 Exisulind also induced apoptosis as determined by DNA fr

6 Sulindac sulfone (exisulind), although a nonsteroidal anti-inflammatory dr

7 and PDE2 gene families that are inhibited by exisulind and new synthetic analogues.

8 nergistic interactions for sulindac sulfide, exisulind, and NDGA with paclitaxel, cisplatin, and 13-c

9 Exisulind (Aptosyn) is a novel antineoplastic drug being

10 s in cancer cells, because sulindac sulfone (exisulind, Aptosyn) and certain derivatives that inhibit

11 an colon cancer cells with sulindac sulfone (Exisulind, Aptosyn) or the related derivative OSI-461, b

12 hosphodiesterase inhibitor sulindac sulfone (exisulind, aptosyn, hereafter called exisulind) led to i

13 hed to an experimental diet containing 0.12% exisulind at 14 weeks after the second AOM treatment.

14 Exisulind at doses of 800, 1000, and 1200 mg/kg (diet) i

15 Administration of 0.06% and 0.12% exisulind during the initiation and postinitiation perio

16 administration of the higher dose (0.12%) of exisulind during the promotion/progression stage had onl

17 s to conclude that future clinical trials of exisulind for human bladder cancer treatment and/or prev

18 studied the safety and clinical activity of exisulind in combination with capecitabine in 35 patient

19 ith the PKG inhibitor Rp-8-pCPT-cGMP blocked Exisulind-induced 15-LOX-1 expression.

20 bladder tumor cell line, HT1376, showed that exisulind inhibited growth with a GI(50) of 118 microM,

21 ulfone (exisulind, aptosyn, hereafter called exisulind) led to increased expression of the tumor supp

22 We studied the effect of exisulind on bladder tumorigenesis induced in rats by th

23 e have also studied the modulating effect of exisulind on colonic tumor apoptosis.

24 Exisulind, OSI-461, and 8-pCPT-cGMP also increased mRNA

25 +/- retinoic acid +/- NDGA) and therapeutic (exisulind +/- paclitaxel +/- cisplatin) studies in patie

26 ies provide a rationale for chemoprevention (exisulind +/- retinoic acid +/- NDGA) and therapeutic (e

27 n to be a substrate for PKG, is decreased by exisulind, suggesting a mechanism to explain apoptosis i

28 t treatment of human colon cancer cells with exisulind (sulindac sulfone) and related compounds induc

29 lindac sulfide, a COX-1 and COX-2 inhibitor; exisulind (sulindac sulfone), a novel proapoptotic agent

30 Treatment of the cells with Exisulind, sulindac sulfide, OSI-461, the guanylyl cycla

31 hemopreventive efficacy of sulindac sulfone (exisulind), the sulfone metabolite of sulindac, when adm

32 A novel mechanism for exisulind to induce apoptosis is studied involving susta

33 The inhibition of colon tumorigenesis by exisulind was associated with a significant retardation

34 Two dose levels of exisulind were explored, 125 and 250 mg orally bid as co

35 promotion/progression study and receiving 0% exisulind were switched to an experimental diet containi

36 ency (IC50 = 4-80 microM), and cisplatin and exisulind were the least potent (IC50 = 150-500 microM).

37 DE5 and PDE4 isozymes that were inhibited by exisulind with IC(50)s of 112 and 116 microM, respective

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。